509
Participants
Start Date
May 31, 2012
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
PP3M 175 mg eq.
Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
PP3M 263 mg eq.
Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
PP3M 350 mg eq.
Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
PP3M 525 mg eq.
Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Placebo (20% Intralipid emulsion)
Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Little Rock
San Fran Cisco
Washington D.C.
Lauderhill
Chicago
Hoffman Estates
Topeka
Baltimore
Flowood
Marlton
Cedarhurst
Oklahoma City
Austin
Dallas
Salt Lake City
Barranquilla
Bogotá
Medellín
Pereira
Johor Bahru
Kuala Lumpur
Tanjong Rambutan
Guadajalara
Mexico City
Monterrey
San Luis Potosí City
Zapopan
Arad
Craiova
Iași
Sibiu
Tg Mures
Deajun
Gyeongsangnam-Do
Incheon
Seongnam
Diyarbakır
Sakarya
Donetsk
Evpatoriya
Hlevakha
Ivano-Frankivsk
Kerch
Kharkiv
Kherson
Kiev
Lviv
Odesa
Poltava
Smila
Ternopil
Uzhhorod
Vinnitsa
Janssen Research & Development, LLC
INDUSTRY